Finance

Developer, manufacturer of human cell lines reports 2004 results

Published in Gene Therapy Weekly, March 24th, 2005

Vitro Diagnostics, Inc. (VODG) announced the filing of its annual report for fiscal year 2004 with the U.S. Securities and Exchange Commission.

For the year ended October 31, 2004, the company reported a net loss of $186,858 or $0.02/share on product revenue of $929. The 2004 net loss was a reduction of $75,420 from the net loss reported in 2003.

Also, the company's fiscal year 2004 report details the status of the initial commercialization of its Vitrocell product line and its current research regarding the development of new methods for the growth and development of human pancreatic beta islets (Islets of Langerhans) from human stem cells.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2005-03-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry